A financial model for an impact investment fund for the development of antibacterial treatments and diagnostics

  05 June 2020

This financial model was prepared as part of an overall project on setting up an impact investment fund to foster development of new antibacterial treatments. It can be used by any company, private or public investor to model cost, and risk of antibiotic development. It may also assist public entities and decision makers in calculating the possible amount and assessing the impact of instruments such as market entry rewards or milestone prizes to pull more investment into antibiotic research.

The model is not meant to provide advice on individual investment decisions.

Further reading: WHO
Author(s): WHO
Smart Innovations  

Display your AMR technology / product:

Global AMR Technologies Database

  • Preventive – Diagnostic – Antimicrobial technologies
  • Academia – Research Institutes – Start ups – SMEs – Multinationals
  • Early research <-> near market
  • Global reach for funding / co-development / licensing
Display your technology and make use of the Continuous AMR Partnering Initiative >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!